Clinical trial
A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic…
NCT00076401 · Pharmacyclics LLC., Industry · Terminated
Key facts
| NCT number | NCT00076401 |
|---|---|
| Title | A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL) |
| Official title | Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Chronic |
| Intervention type | Drug |
| Interventions | Motexafin gadolinium |
| Enrollment | 27 |
| First posted | Jan 26, 2004 |
| Last update posted | Jun 26, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: